<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597595</url>
  </required_header>
  <id_info>
    <org_study_id>2771/09/14</org_study_id>
    <nct_id>NCT02597595</nct_id>
  </id_info>
  <brief_title>Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major</brief_title>
  <official_title>Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the cardioprotective effect of spirulina in children
      with beta thalassemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the cardioprotective effect of spirulina in children
      with beta thalassemia.

      this study will be carried on thirty children with beta thalassemia major from those
      attending the Hematology Unit of Pediatric department at Tanta University Hospital, and
      another thirty healthy children of matched age and sex will be enrolled as controls.

      all studied children will be subjected to careful history taking and through clinical
      examination. laboratory investigations will be done including complete blood count,
      hemoglobin electrophoresis, serum ferritin, liver and kidney functions, and troponin-1 plasma
      level. echocardiographic assessment of the cardiac functions will be done for all patients.
      Source data will be the patients medical records.

      oral spirulina will be given for studied patients for 3 months, and clinical examination,
      laboratory investigations and cardiac functions will be assessed at the time of inclusion in
      the study, and again after 3 months of regular spirulina supplementation.

      An informed consent will be obtained from parents of all included subjects. the results of
      this study will be tabulated and statistically analyzed using Statistical Package for the
      Social Sciences (SPSS).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cardiac functions measured by echocardiography</measure>
    <time_frame>after 3 months of regular oral spirulina supplementation</time_frame>
    <description>Fractional shortening [FS]. Mitral flow early phase filling velocity [E], peak atrial phase filling velocity[A] and E/A ratio, and left ventricular (LV) diastolic function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac functions measured by troponin-1 plasma level.</measure>
    <time_frame>after 3 months of regular oral spirulina supplementation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Beta Thalassemia</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>thirty children with beta thalassemia major, with age range from 4-18 years, will receive oral spirulina (tablets=500 mg) for 3 months with a dose of 250 mg/kg/day (maximum dose 4 gm)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>thirty healthy children of matched age and sex</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>spirulina</intervention_name>
    <description>oral spirulina (tablet=500mg) will be given to patients for 3 months in a dose of 250 mg/kg/day (maximum 4 gm)</description>
    <arm_group_label>patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children suffering from beta thalassemia major with age range from 4-18 years

        Exclusion Criteria:

          -  children with congenital heart diseases children with rheumatic heart diseases
             presence of heart failure children with coronary arterial disease children with
             cardiomyopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magda M Ibrahim, M.B.B.ch</last_name>
    <role>Principal Investigator</role>
    <affiliation>Master Degree student</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Osama AR Tolba, MD</last_name>
    <role>Study Chair</role>
    <affiliation>supervisor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rasha M Gamal, MD</last_name>
    <role>Study Director</role>
    <affiliation>supervisor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine- Tanta University</name>
      <address>
        <city>Tanta</city>
        <state>Gharbia</state>
        <zip>0000</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Khan M, Shobha JC, Mohan IK, Naidu MU, Sundaram C, Singh S, Kuppusamy P, Kutala VK. Protective effect of Spirulina against doxorubicin-induced cardiotoxicity. Phytother Res. 2005 Dec;19(12):1030-7.</citation>
    <PMID>16372368</PMID>
  </reference>
  <reference>
    <citation>Cogliandro T, Derchi G, Mancuso L, Mayer MC, Pannone B, Pepe A, Pili M, Bina P, Cianciulli P, De Sanctis V, Maggio A; Society for the Study of Thalassemia and Hemoglobinopathies (SoSTE). Guideline recommendations for heart complications in thalassemia major. J Cardiovasc Med (Hagerstown). 2008 May;9(5):515-25. doi: 10.2459/JCM.0b013e3282f20847.</citation>
    <PMID>18404006</PMID>
  </reference>
  <reference>
    <citation>Pennell DJ, Udelson JE, Arai AE, Bozkurt B, Cohen AR, Galanello R, Hoffman TM, Kiernan MS, Lerakis S, Piga A, Porter JB, Walker JM, Wood J; American Heart Association Committee on Heart Failure and Transplantation of the Council on Clinical Cardiology and Council on Cardiovascular Radiology and Imaging. Cardiovascular function and treatment in Î²-thalassemia major: a consensus statement from the American Heart Association. Circulation. 2013 Jul 16;128(3):281-308. doi: 10.1161/CIR.0b013e31829b2be6. Epub 2013 Jun 17. Erratum in: Circulation. 2013 Sep 24;128(13):e203.</citation>
    <PMID>23775258</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Professor Mohamed Elshanshory</investigator_full_name>
    <investigator_title>professor and head of hematology and oncology unit at pediatric department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

